SLC6A3 and Parkinson disease: Our group recently demonstrated that PD patients with a combination of reduced CSF Aβ42, increased CSF total tau and reduced caudate DAT uptake had a 65% risk of developing CI, defined by Level 2 criteria, at 36-month follow-up (Yousaf et al. 2019).